HighTower Advisors’s Sonoma Pharmaceuticals SNOA Stock Holding History

HighTower Advisors’s Portfolio SNOA Stock Details SNOA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-505	Closed	-$85K	–	2792
2020 Q3	$85K	Buy	+505	New	+$77.7K	﹤0.01%	2253

Other funds holding SNOA

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Bard Associates Chicago, Illinois $398M AUM 54.32% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RBC Europe London, United Kingdom $2.08B AUM 12.2% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

US Bancorp Minneapolis, Minnesota $82.4B AUM 19.69% 1-Year Est. Return

HighTower Advisors's SNOA Position: Q4 2020 in Review

HighTower Advisors sold out of Sonoma Pharmaceuticals (SNOA) in Q4 2020, closing a stake of 505 shares — an estimated $85K sold.

HighTower Advisors first reported a position in SNOA in Q3 2020 and held it in 1 quarter. The position peaked at $85K in Q3 2020. 18 funds tracked by Wall St. Rank hold SNOA as of Q4 2020.

HighTower Advisors reported no remaining Sonoma Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
HighTower Advisors sold 505 Sonoma Pharmaceuticals shares in Q4 2020, an estimated $85K.
HighTower Advisors first reported a position in Sonoma Pharmaceuticals in Q3 2020 and held it in 1 quarter.
HighTower Advisors's Sonoma Pharmaceuticals position peaked at $85K in Q3 2020.
18 funds tracked by Wall St. Rank held Sonoma Pharmaceuticals as of Q4 2020.

Based on HighTower Advisors's 13F filing for Q4 2020, filed 10 Feb 2021.